Tysabri Revised RiskMAP Would Have Mandatory Patient/Physician Registry Enrollment
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec’s revised risk management plan for its multiple sclerosis therapy Tysabri adopts most changes sought by FDA in a critique of the company’s original risk plan.